Published in Int J Med Sci on January 22, 2015
Arterial Hypertension Is Characterized by Imbalance of Pro-Angiogenic versus Anti-Angiogenic Factors. PLoS One (2015) 0.77
Association between Benzodiazepine Use and Dementia: Data Mining of Different Medical Databases. Int J Med Sci (2016) 0.76
Statin use and all-cause and cancer mortality: BioBank Japan cohort. J Epidemiol (2017) 0.75
Adherence to dipeptidyl peptidase-4 inhibitor therapy among type 2 diabetes patients with employer-sponsored health insurance in Japan. J Diabetes Investig (2016) 0.75
Variability in statin-induced changes in gene expression profiles of pancreatic cancer. Sci Rep (2017) 0.75
Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation (2002) 76.93
Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med (1995) 28.35
Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet (2002) 17.19
Calculating confidence intervals for relative risks (odds ratios) and standardised ratios and rates. Br Med J (Clin Res Ed) (1988) 7.41
Carcinogenicity of lipid-lowering drugs. JAMA (1996) 7.04
Statins and cancer risk: a meta-analysis. JAMA (2006) 6.28
Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev (2013) 5.57
Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. J Am Coll Cardiol (2007) 4.93
CD4+CD25+Foxp3+ regulatory T cells induce alternative activation of human monocytes/macrophages. Proc Natl Acad Sci U S A (2007) 4.24
Report of the Conference on Low Blood Cholesterol: Mortality Associations. Circulation (1992) 3.98
Quantitative signal detection using spontaneous ADR reporting. Pharmacoepidemiol Drug Saf (2009) 3.96
A Bayesian neural network method for adverse drug reaction signal generation. Eur J Clin Pharmacol (1998) 3.88
Tregs and rethinking cancer immunotherapy. J Clin Invest (2007) 3.77
Mortality and incidence of cancer during 10-year follow-up of the Scandinavian Simvastatin Survival Study (4S). Lancet (2004) 3.59
The association between statins and cancer incidence in a veterans population. J Natl Cancer Inst (2008) 3.40
Statins have biphasic effects on angiogenesis. Circulation (2002) 3.39
Immunosenescence of ageing. J Pathol (2007) 3.32
Synchronization of tumor and normal cells from G1 to multiple cell cycles by lovastatin. Cancer Res (1991) 3.24
Statin use and the risk of 10 cancers. Epidemiology (2007) 3.17
Outcomes of using high- or low-dose atorvastatin in patients 65 years of age or older with stable coronary heart disease. Ann Intern Med (2007) 3.13
The risk of cancer in users of statins. J Clin Oncol (2004) 3.01
A comparison of measures of disproportionality for signal detection in spontaneous reporting systems for adverse drug reactions. Pharmacoepidemiol Drug Saf (2002) 2.98
HMG-CoA reductase inhibitors and the malignant cell: the statin family of drugs as triggers of tumor-specific apoptosis. Leukemia (2002) 2.89
3-hydroxy-3-methylglutaryl-coenzyme a reductase inhibitors reduce human pancreatic cancer cell invasion and metastasis. Gastroenterology (2002) 2.84
Statins, low-density lipoprotein cholesterol, and risk of cancer. J Am Coll Cardiol (2008) 2.77
Screening statins for possible carcinogenic risk: up to 9 years of follow-up of 361,859 recipients. Pharmacoepidemiol Drug Saf (2008) 2.43
Statin use and cancer risk in the General Practice Research Database. Br J Cancer (2004) 2.34
Statins and cancer: A systematic review and meta-analysis. Eur J Cancer (2008) 2.15
Development of a database of health insurance claims: standardization of disease classifications and anonymous record linkage. J Epidemiol (2010) 2.12
Novel statistical tools for monitoring the safety of marketed drugs. Clin Pharmacol Ther (2007) 2.12
Statins and cancer risk. Am J Med (2008) 2.09
Reports of hypoglycaemia associated with the use of ACE inhibitors and other drugs: a case/non-case study in the French pharmacovigilance system database. Br J Clin Pharmacol (1997) 2.02
Statins and risk of cancer: a systematic review and metaanalysis. Int J Cancer (2007) 2.00
Benefits of pravastatin on cardiovascular events and mortality in older patients with coronary heart disease are equal to or exceed those seen in younger patients: Results from the LIPID trial. Ann Intern Med (2001) 1.97
Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy. PLoS One (2012) 1.93
Serum cholesterol and the incidence of cancer in a large cohort. J Chronic Dis (1986) 1.87
The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. Atherosclerosis (2007) 1.87
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res (2002) 1.79
Evidence of depression provoked by cardiovascular medication: a prescription sequence symmetry analysis. Epidemiology (1996) 1.78
Long-term use of cholesterol-lowering drugs and cancer incidence in a large United States cohort. Cancer Res (2011) 1.76
Statin use and breast cancer: prospective results from the Women's Health Initiative. J Natl Cancer Inst (2006) 1.70
Statin use and cancer risk: a comprehensive review. Expert Opin Drug Saf (2010) 1.56
Data mining of the public version of the FDA Adverse Event Reporting System. Int J Med Sci (2013) 1.56
Antimicrobials and the risk of torsades de pointes: the contribution from data mining of the US FDA Adverse Event Reporting System. Drug Saf (2010) 1.53
Incidence of cancer and statin usage--record linkage study. Int J Cancer (2010) 1.51
Endogenous DNA damage as related to cancer and aging. Mutat Res (1989) 1.41
Drug-induced torsades de pointes: data mining of the public version of the FDA Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug Saf (2009) 1.39
Serum cholesterol and risk of cancer in a cohort of 39,000 men and women. J Clin Epidemiol (1988) 1.38
Association of low plasma cholesterol with mortality for cancer at various sites in men: 17-y follow-up of the prospective Basel study. Am J Clin Nutr (2000) 1.35
Exposure to statins and risk of common cancers: a series of nested case-control studies. BMC Cancer (2011) 1.29
Blocking protein geranylgeranylation is essential for lovastatin-induced apoptosis of human acute myeloid leukemia cells. Leukemia (2001) 1.27
Inverse association between serum total cholesterol and cancer mortality in Dutch civil servants. Am J Epidemiol (1993) 1.22
Reduction of mouse mammary tumor formation and metastasis by lovastatin, an inhibitor of the mevalonate pathway of cholesterol synthesis. Breast Cancer Res Treat (1998) 1.19
Microarray and biochemical analysis of lovastatin-induced apoptosis of squamous cell carcinomas. Neoplasia (2002) 1.11
Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor. Ther Clin Risk Manag (2011) 1.11
Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TEXCAPS): additional perspectives on tolerability of long-term treatment with lovastatin. Am J Cardiol (2001) 1.10
The waiting time distribution as a graphical approach to epidemiologic measures of drug utilization. Epidemiology (1997) 1.07
Adverse events with use of antiepileptic drugs: a prescription and event symmetry analysis. Pharmacoepidemiol Drug Saf (2009) 1.03
Statin use in primary inflammatory breast cancer: a cohort study. Br J Cancer (2013) 1.00
Inhibitory effect of Lovastatin on spontaneous metastases derived from a rat lymphoma. Clin Exp Metastasis (1999) 0.96
Pravastatin use and the five-year incidence of cancer in coronary heart disease patients: from the prevention of coronary sclerosis study. J Epidemiol (2006) 0.92
Simvastatin induces death of multiple myeloma cell lines. J Investig Med (2004) 0.91
Atorvastatin: a potential chemopreventive agent in bladder cancer. Urology (2005) 0.87
Regulatory T lymphocytes: pivotal components of the host antitumor response. J Clin Oncol (2007) 0.85
Aspirin- and clopidogrel-associated bleeding complications: data mining of the public version of the FDA adverse event reporting system, AERS. Int J Med Sci (2012) 0.83
Statin use may improve clinicopathological characteristics and recurrence risk of invasive breast cancer. Med Oncol (2014) 0.77
Statin use and the risk of bladder cancer: a population-based case-control study. Expert Opin Drug Saf (2012) 0.77
Lower serum levels of total cholesterol are associated with higher urinary levels of 8-hydroxydeoxyguanosine. Nutr Metab (Lond) (2013) 0.77
Statin treatment does not cause cancer. J Am Coll Cardiol (2008) 0.77